Amorepacific Research Confirms Potential of Microalgal-Derived PDRNs in Skin Regeneration and Wound Healing

New findings suggest 'BluePDRNâ„¢' offers a sustainable, scalable alternative to traditional animal-derived PDRNs

SEOUL, South Korea, April 29, 2025 /PRNewswire/ -- Amorepacific revealed research findings confirming the skin-regenerative effects of polydeoxyribonucleotides (PDRNs) extracted from a microalgal source, Chlorella protothecoides. The findings were published in the international journal Archives of Dermatological Research under the title, "Effects of Chlorella protothecoides-derived polydeoxyribonucleotides on skin regeneration and wound-healing."

PDRNs have been garnering attention in recent years for its efficacy in enhancing skin regeneration and wound healing. In Korea, PDRNs that have been purified can be found in various applications, including pharmaceuticals, medical devices and cosmetics. Traditionally, PDRNs are extracted from animal-derived sources like salmon or trout, but Amorepacific turned its attention to Chlorella protothecoides to develop an animal-free alternative that is sustainable and scalable.

The pioneering research on Chlorella-derived PDRNs, led by Amorepacific's R&I Center, was conducted as part of the Ministry of Oceans and Fisheries' project to develop marine biomaterial formulation technology. Through this initiative, Amorepacific successfully developed a production process for high-yield, low-molecular-weight, microalgal-derived PDRNs dubbed 'BluePDRNâ„¢', consequently shedding light on its mechanism of action and skin regenerative effects.

Research results showed BluePDRNâ„¢ displayed wound closure effects equivalent to those of salmon-derived PDRN^[1], with each molecule being approximately 1/20th the size of a salmon-derived PDRN molecule^[2]. It also promoted the expression of collagen accumulation and angiogenesis, both of which are essential for healthy skin. Like traditional animal-derived PDRNs, BluePDRNâ„¢ demonstrated skin regeneration efficacy through an adenosine A2A receptor (A2AR)-dependent mechanism.

Notably, the regenerative benefits of BluePDRN^TM were also observed in skin tissue with epidermal damage caused by photoaging, as demonstrated in experiments conducted by Outer Biosciences Inc., a biotechnology company in Boston, MA, USA that researches ingredients for skin health.

Byung-Fhy Suh, CTO of Amorepacific R&I Center, said, "This research is highly significant as it reveals the efficacy of sustainable, vegan PDRNs derived from microalgae. Amorepacific will continue its efforts to deliver safer and more effective products to customers around the world."

Amorepacific has applied for a patent on the production technology behind BluePDRNâ„¢, "Manufacturing technology for low-molecular-weight PDRN isolated from microalgae (Chlorella) using a continuous modular process." The company has also received a New Excellent Technology (NET) certification and a minister's commendation from the Ministry of Oceans and Fisheries.

^[1] Results from Amorepacific R&I Center tests on ex vivo skin and reconstructed human epidermis

^[2] Each BluePDRNâ„¢ being approximately 24 kDa in size (1/20^th the size of a salmon-derived PDRN molecule), according to measurement of molecular weight by Korea Polymer Testing & Research Institute

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Amorepacific Research Confirms Potential of Microalgal-Derived PDRNs in Skin Regeneration and Wound Healing

Amorepacific Research Confirms Potential of Microalgal-Derived PDRNs in Skin Regeneration and Wound Healing

SEOUL, South Korea, May 16, 2025 /PRNewswire/ -- Korean healthtech company MINISH Technology hosted a successful dental seminar and business briefing in Los Angeles on May 10th, marking its second international event and a key step in its North American expansion - following its successful launch in Tokyo. 

Following its inaugural overseas seminar in Tokyo earlier this year, MINISH Veneers brought its advanced veneer solution and minimally invasive restorative philosophy to a U.S. audience. The six-hour event, held at The West Hollywood EDITION, welcomed more than 80 local dentists from across the U.S..

The program introduced MINISH veneers' proprietary restorative system, presented real-world clinical cases, and outlined the company's plans to build a provider network in the U.S. Speakers also shared insights into practice models from established MINISH veneers providers in Asia and the company's broader North American strategy.

"To present our solution in one of the world's most advanced dental markets is an incredible milestone," said a MINISH spokesperson. "With our first U.S. provider clinic already operating in Los Angeles, we're now focused on expanding our footprint across North America."

MINISH Veneers currently operates 75 provider clinics worldwide, including 43 in Korea, 29 in Japan, and one clinic each in the U.S., Canada, and Vietnam. Out of the respondents, more than 81% of dentists present at the seminar expressed interest in joining the MINISH veneers provider network.

About MINISH Technology

MINISH Technology Co., Ltd. is a Seoul-based healthtech company offering cutting-edge solutions in restorative and aesthetic dentistry. Its signature MINISH system restores damaged teeth with precision-fabricated restorations that preserve natural tooth structure.

In addition to its clinical platform, MINISH operates the MINISH Veneers Course for dentist education, manages the MINISH Provider network, and invests in R&D across dental materials, equipment, and digital oral health technologies.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

MINISH Veneers Expands Global Footprint with Successful Dental Seminar in Los Angeles